Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03374332
Recruitment Status : Recruiting
First Posted : December 15, 2017
Last Update Posted : June 5, 2020
Sponsor:
Collaborators:
Brown University
Rhode Island Hospital
The Miriam Hospital
Pfizer
Information provided by (Responsible Party):
John Reagan, Brown University

Brief Summary:

This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available. Researchers are studying whether the drug Gemtuzumab Ozogamicin, followed by an infusion of blood cells called leukocytes from a donor, can stimulate the immune system to potentially fight the leukemia. Gemtuzmab ozogamicin is a class of drugs known as an antibody drug conjugate. The drug is given on days 1,4,7. It is infused, attaches to cells with a certain marker on the surface (the majority of which would be leukemia cells). The drug is then internalized and the chemotherapy drug becomes activated. Gemtuzumab is currently FDA approved for the treatment of acute myeloid leukemia.

The infusion of leukocytes to stimulate the immune system to fight your leukemia is investigational and has not been proven to cure cancer. This combination of Gemtuzumab Ozogamicin and donor leukocytes is not an FDA approved treatment and is investigational.

Initially a total of 6 patients will be included in the study to assess the safety of the treatment. Once 6 patients have been treated and no unacceptable toxicities are seen, more patients will be enrolled. The study will treat up to 18 patients on the study.


Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Gemtuzumab Ozogamicin (GO) Other: Donor Leukocytes Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Actual Study Start Date : December 31, 2019
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2022


Arm Intervention/treatment
Experimental: Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1

Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)

Patients < 70 years old: GO 9mg/m2 (3mg/m2 each dose)

Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^7 CD3+ cells and maximum of 2x10^7 CD3+ cells/kg irrespective of the number of CD34+ cells.

Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion.

Drug: Gemtuzumab Ozogamicin (GO)
Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
Other Name: Mylotarg

Other: Donor Leukocytes
The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.

Experimental: Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2

Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)

Patients: < 70 years old: GO 9mg/m2 (3mg/m2 each dose)

Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^8 CD3+ cells and maximum of 2x10^8 CD3+ cells/kg irrespective of the number of CD34+ cells.

Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion.

Drug: Gemtuzumab Ozogamicin (GO)
Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
Other Name: Mylotarg

Other: Donor Leukocytes
The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.




Primary Outcome Measures :
  1. Response Rate [ Time Frame: Post infusion for a total of 2 years. ]

    Response rate of infusional gemtuzumab ozogamicin followed by nonengraftment donor leukocyte infusions in patients with refractory acute myeloid leukemia.

    Bone Marrow Biopsy to be done in patients thought to have responded.



Secondary Outcome Measures :
  1. Survival [ Time Frame: Through 2 years post end of treatment ]
    Progression free survival and overall survival of infusional gemtuzumab ozogamicin followed by nonengraftment donor leukocyte infusions in patients with refractory acute myeloid leukemia.

  2. Dose limiting toxicities [ Time Frame: Start of treatment through 16 weeks post the final infusion ]
    Rate of dose limiting toxicities of gemtuzumab ozogamicin followed by nonengraftment donor leukocyte infusions in patients with refractory acute myeloid leukemia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria of Recipient (patient):

  • Histologic confirmation of acute myeloid leukemia (AML)
  • Recurrence or progression (including refractory disease) of AML after at least 1 prior standard treatment with progression within 6 months from last treatment.
  • No curative treatment option is available
  • ≥ 4-weeks since prior chemotherapy or radiation to cellular therapy infusion.
  • Age equal to or greater than 18 years.
  • Patients with a history of invasive second malignancy who are disease free for ≥ 2 years.
  • Patients must have an expected life expectancy of at least 2 months at the time of initiation of treatment
  • No active systemic infections allowed.
  • Patients who have relapsed after standard autologous stem cell infusion are eligible as long as they meet all inclusion criteria and no exclusion criteria. These patients must be out more than 6 months from cell infusion to be eligible for enrollment.
  • DLCO ≥ 40% with no symptomatic pulmonary disease.
  • LVEF ≥ 40% by MUGA or echocardiogram.
  • Creatinine <1.5x ULN or any serum creatinine level associated with a measured or calculated creatinine clearance of >40 mL/min, AST and ALT < 2.5x ULN, Total Bilirubin < 1.5 x ULN
  • Women of childbearing potential and sexually active males must use 2 forms of effective contraception method from time of consent through 6 months after completing treatment (whether last treatment is infusion or drug).
  • Not pregnant or nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment (drug). Post-menopausal women (surgical menopause or lack of menses ≥12 months) do not need to have a pregnancy test, please document status.
  • Performance status ≤ 2 (or KPS 70)

Exclusion Criteria of Recipient (patient):

  • Evidence of HIV infection.
  • Any uncontrolled severe, concurrent illness which in the opinion of the treating physician would make this protocol treatment unreasonably hazardous for the patient.
  • Oxygen dependent obstructive pulmonary disease.
  • Failure to demonstrate adequate compliance with medical therapy and follow-up
  • Significant medical or psychiatric illness that would impair the ability to participate in protocol therapy.
  • Previous allogeneic stem cell transplant
  • Patients who have had previous purine analog (fludarabine, pentostatin, 2-CDA) treatment or treatment with alemtuzumab within 1 year of entering the study
  • Previous history of Veno-occlusive disease/Sinusoidal Obstruction Syndrome
  • Active hepatitis B or C
  • Patients with known active central nervous system leukemia
  • Patients with prior treatment of Gemtuzumab ozogamicin
  • Patients eligible for allogeneic stem cell transplant

Donor Eligibility Criteria * donor eligibility must be documented and assessed by a separate participating physician other than the treating physician of the recipient.

  • Donors agree to up to 3 donor leukocyte collections as documented by assessing physician (although it is not required that the same donor is used for all leukocyte infusions it is preferable, therefore agreement is important at screening). This must be documented in writing by treating physician.
  • Typing is required at the following loci: HLA A, B, C, and DRB1.
  • Patients with a HLA 0/6 to 3/6(using loci A, B, DR) donor match will be able to participate in this protocol.
  • Donors must be a first degree relative.
  • CMV titer negative donors are preferred above CMV titer positive donors if the patient is CMV positive. If the patient is CMV negative, only CMV negative donors are eligible.
  • Although ABO blood type matching is not required given use of apheresis product preference will be made to ABO compatible donors
  • Donors must be ≥18 years of age to donate.
  • Donor with a history of malignancy other than non-melanoma skin cancers are eligible only if they had a history of a solid tumor malignancy more than five years prior to lymphocyte donation, and are considered to be in longstanding complete remission as documented by a physician. The donor must be healthy and have all testing criteria completed and meet all criteria for stem cell donation.
  • The donor will also be assessed by physician who will document behavioral risk for exposure to infectious agents and diseases.Testing will include the following: Human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease, communicable disease risks associated with xenotransplantation, Chlamydia trachomatis and for Neisseria gonorrhea, Treponema pallidum (syphilis).This will exclude the donor.
  • The donor must be in good general health and not have significant cardiopulmonary, renal, endocrine, or hepatic disease as documented in writing by physician.
  • B-HCG urine or serum negative if donor is of childbearing potential within 7 days of PBMC procurement. Not applicable for donors who are Post-menopausal (surgical menopause or lack of menses ≥12 months).
  • Donors must have adequate venous access so leukapheresis can be performed via standard peripheral IV without the need for placement of a central venous catheter.

Donor Exclusion Criteria:

  • HLA to which the patient has anti-HLA antibody (ies)
  • Evidence of infection for HIV-1, HIV-2, syphilis, hepatitis B or C, HTLV 1 or 2, WNV, Chagas, Zika.
  • Uncontrolled diabetes mellitus. If donor has controlled diabetes this must be documented by physician.
  • Active or congestive heart failure syndrome from any cause per donor medical history. Approval for participation by Cardiologist required to be sent to BrUOG.
  • Full cardiac workup by a Cardiologist is required for any history of congestive heart failure syndrome, conduction abnormalities or history of arrhythmia other than treated atrial fibrillation.
  • Active angina pectoris. To be documented by physician
  • Oxygen dependent pulmonary disease. To be documented by physician
  • History of any lymphoid, myeloid or other non-solid malignancy. To be documented by physician
  • Failure to receive full informed consent.
  • Inadequate renal and/or hepatic function per medical history. To be documented by physician
  • Known history of cirrhosis or active liver disease per medical history. To be documented by physician
  • History of transplantation. To be documented by physician.
  • Donor with a diagnosis of Zika in the past 6 months, or who lived in or traveled to an area with increased risk for Zika in the past 6 months, or who had sex in the past 6 months with a person who has the risks of either having been diagnosed or lived in or traveled to areas with increased risk.
  • A donor in whom plasma dilution sufficient to affect the results of communicable disease testing is suspected, unless: (A) You test a specimen taken from the donor before transfusion or infusion and up to 7 days before recovery of cells or tissue; or (B) You use an appropriate algorithm designed to evaluate volumes administered in the 48 hours before specimen collection, and the algorithm shows that plasma dilution sufficient to affect the results of communicable disease testing has not occurred.
  • Clinical situations in which you must suspect plasma dilution sufficient to affect the results of communicable disease testing will exclude the donor. Such situations include, but are not limited to the following:(A) Blood loss is known or suspected in a donor over 12 years of age, and the donor has received a transfusion or infusion of any of the following, alone or in combination:

    1. More than 2,000 milliliters (mL) of blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or
    2. More than 2,000 mL of crystalloids within 1 hour before death or specimen collection, whichever occurred earlier.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03374332


Contacts
Layout table for location contacts
Contact: Roxanne Wood, BA, CCRC 401-863-3000 roxanne_wood@brown.edu

Locations
Layout table for location information
United States, Rhode Island
Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Roxanne Wood, BA, CCRC    401-863-3000    Roxanne_Wood@brown.edu   
Principal Investigator: John Reagan, MD         
Sponsors and Collaborators
John Reagan
Brown University
Rhode Island Hospital
The Miriam Hospital
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: John Reagan, MD Brown University Oncology Research Group (BrUOG)
Layout table for additonal information
Responsible Party: John Reagan, Principal Investigator: Sponsor-Investigator, Brown University
ClinicalTrials.gov Identifier: NCT03374332    
Other Study ID Numbers: BrUOG 345
First Posted: December 15, 2017    Key Record Dates
Last Update Posted: June 5, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by John Reagan, Brown University:
Refractory
progression
recurrence
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Gemtuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents